Therefore, we can monitor the thyroid hormone level of patients, and give low dose of thyroxine when necessary to maintain the higher level of FT4 level in the normal range, so as to reduce the occurrence and development of LEAD in T2DM patients. This evidence concerns the gene TG and type 2 diabetes mellitus.